{
  "title": "M21-1, Part VIII, Subpart iii, Chapter 5, Section B - Rating Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing",
  "url": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177458/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-B-Rating-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing",
  "content": "<-- Previous Section\nNext Section -->\nOverview\nIn This Section\nThis section contains the topic “\nRating Claims Based on Participation in CBRNE Testing\n.”\n1\n.\nRating Claims Based on CBRNE Testing\nIntroduction\nThis topic contains information on rating claims based on CBRNE testing, including\nconsidering service connection (SC) based on CBRNE test participation\nreviewing an examination and medical opinion for claims based on CBRNE testing\n, and\nCBRNE rating requirements\n.\nChange Date\nMarch 17, 2025\nVIII.iii.5.B.1.a\n.\nConsidering SC Based on CBRNE Test Participation\nThere are no presumptive conditions or disabilities recognized as common to chemical, biological, radiological, nuclear, and explosives (CBRNE) testing.  The determination of whether to award service connection (SC) for a disease or injury claimed as related to participation in CBRNE testing falls under the direct SC provisions.  Decisions to award or deny SC should also consider all exposures the Veteran incurred in all documented toxic exposure risk activity (TERA) participation, to include CBRNE testing.\nReferences\n:  For more information on\ndevelopment and other considerations for CBRNE claims, see\nM21-1, Part VIII, Subpart iii, 5.A\ndirect SC, see\n38 CFR 3.303\n, and\nM21-1, Part V, Subpart ii, 2.A\n, and\nprocessing TERA claims, see the\nSergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022 Implementation Standard Operating Procedure (SOP)\n.\nVIII.iii.5.B.1.b\n.\nReviewing an Examination and Medical Opinion for Claims Based on CBRNE Testing\nWhen reviewing an examination and medical opinion for claims based on CBRNE testing, ensure that the examination report meets the TERA examination sufficiency requirements as outlined in the\nPACT Act Implementation SOP\n.\nReference\n:  For more information on sufficiency of examination reports, see\nM21-1, Part IV, Subpart i, 3.A\n.\nVIII.iii.5.B.1.c\n.\nCBRNE Rating Requirements\nIn addition to the general rating narrative requirements outlined in\nM21-1, Part V, Subpart iv, 1.A\n, CBRNE rating decisions must follow the below guidelines.\nSince CBRNE is considered TERA participation, the rating decision must follow the TERA rating guidance outlined in the\nPACT Implementation SOP\n.\nWhen denying SC because an\nexplicit\nallegation of CBRNE test participation could not be established, the rating decision must include the following free text to the rating narrative:\nYou reported participating in Chemical Biological Radiological Nuclear and Explosives (CBRNE) testing. The evidence of record does not show you participated in CBRNE testing\n.\nWhen completing the SUBJECT field on the ISSUE MANAGEMENT tab in Veterans Benefits Management System – Rating (VBMS-R), end the description of the disability with\n[CBRNE]\nregardless of whether the issue is being awarded or denied.  This will clearly identify the CBRNE claimed issues, or those issues which the decision maker has decided are related to CBRNE testing, on the\nCodesheet\n.\nExample\n:\nScar, right upper extremity [CBRNE]\n.\nReference\n:  For more information on entering decisions in VBMS-R, see the\nVBMS Rating User Guide\n.\n<-- Previous Section\nNext Section -->\nTo Top",
  "content_html": "<div class=\"article-content\">\n<div compile-custom=\"article.content\" ng-aria=\"articleContent\"><p class=\"ng-scope\"></p><div class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: Arial,Helvetica,sans-serif\"><a articleid=\"554400000177457\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">&lt;-- Previous Section</a>  <a articleid=\"554400000177459\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 6, Section A - Developing Claims Based on Participation in Project Shipboard Hazard and Defense (SHAD)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177459/M21-1-Part-VIII-Subpart-iii-Chapter-6-Section-A-Developing-Claims-Based-on-Participation-in-Project-Shipboard-Hazard-and-Defense-SHAD\">Next Section --&gt;</a></span></span></div><h2 class=\"ng-scope\"><a id=\"top\" name=\"top\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">Overview</span></span></a></h2><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><th scope=\"row\" style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">In This Section</span></span></h3></th><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This section contains the topic “<a href=\"#1\" target=\"_self\">Rating Claims Based on Participation in CBRNE Testing</a>.”</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/><br/> </div><h2 class=\"ng-scope\"><span style=\"font-size: 16px\"><span style=\"font-family: arial , helvetica , sans-serif\">1<a id=\"1\" name=\"1\">.</a>  Rating Claims Based on CBRNE Testing</span></span></h2><p class=\"ng-scope\"> <br/><br/> </p><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Introduction</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">This topic contains information on rating claims based on CBRNE testing, including</span></span></div><ul><li><div><a href=\"#1a\" target=\"_self\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">considering service connection (SC) based on CBRNE test participation</span></span></a></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1b\" target=\"_self\">reviewing an examination and medical opinion for claims based on CBRNE testing</a>, and</span></span></div></li><li><div><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#1c\" target=\"_self\">CBRNE rating requirements</a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">Change Date</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><font face=\"arial, helvetica, sans-serif\"><span style=\"font-size: 14px;\">March 17, 2025</span></font></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.B.1.a<a id=\"1a\" name=\"1a\">.</a>  Considering SC Based on CBRNE Test Participation</span></span></span></span></span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">There are no presumptive conditions or disabilities recognized as common to chemical, biological, radiological, nuclear, and explosives (CBRNE) testing.  The determination of whether to award service connection (SC) for a disease or injury claimed as related to participation in CBRNE testing falls under the direct SC provisions.  Decisions to award or deny SC should also consider all exposures the Veteran incurred in all documented toxic exposure risk activity (TERA) participation, to include CBRNE testing.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>References</em></strong>:  For more information on </span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">development and other considerations for CBRNE claims, see <a articleid=\"554400000177457\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">M21-1, Part VIII, Subpart iii, 5.A</a></span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">direct SC, see</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a href=\"http://www.ecfr.gov/cgi-bin/text-idx?SID=a88986ca8f9a29e8af73cdffa7bc08f9&amp;node=se38.1.3_1303&amp;rgn=div8\" target=\"_blank\">38 CFR 3.303</a>, and</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><a articleid=\"554400000180481\" articlename=\"M21-1, Part V, Subpart ii, Chapter 2, Section A - Direct Service Connection (SC) and Service Incurrence of an Injury\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180481/M21-1-Part-V-Subpart-ii-Chapter-2-Section-A-Direct-Service-Connection-SC-and-Service-Incurrence-of-an-Injury\">M21-1, Part V, Subpart ii, 2.A</a>, and</span></span></div></li></ul></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">processing TERA claims, see the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>Sergeant First Class Heath Robinson Honoring our Promise to Address Comprehensive Toxics (PACT) Act of 2022 Implementation Standard Operating Procedure (SOP)</i></a>.</span></span></div></li></ul></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.B.1.b<a id=\"1b\" name=\"1b\">.</a>  Reviewing an Examination and Medical Opinion for Claims Based on CBRNE Testing</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When reviewing an examination and medical opinion for claims based on CBRNE testing, ensure that the examination report meets the TERA examination sufficiency requirements as outlined in the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>PACT Act Implementation SOP</i></a>.  </span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><b><i>Reference</i></b>:  For more information on sufficiency of examination reports, see <a articleid=\"554400000180514\" articlename=\"M21-1, Part IV, Subpart i, Chapter 3, Section A - General Criteria for Sufficiency of Examination Reports\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180514/M21-1-Part-IV-Subpart-i-Chapter-3-Section-A-General-Criteria-for-Sufficiency-of-Examination-Reports\">M21-1, Part IV, Subpart i, 3.A</a>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><table border=\"0\" cellpadding=\"0\" cellspacing=\"0\" class=\"ng-scope\" style=\"border-spacing: 0px; border-collapse: revert;\"><tbody><tr><td style=\"width: 115px; vertical-align: top; padding: 0px;\"><h3><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\">VIII.iii.5.B.1.c<a id=\"1c\" name=\"1c\">.</a>  CBRNE Rating Requirements</span></span></h3></td><td style=\"height: 8px; width: 15px; padding: 0px;\"></td><td style=\"width: 516px; padding: 0px;\"><div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">In addition to the general rating narrative requirements outlined in <a articleid=\"554400000180523\" articlename=\"M21-1, Part V, Subpart iv, Chapter 1, Section A - Completing the Rating Decision Narrative\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000180523/M21-1-Part-V-Subpart-iv-Chapter-1-Section-A-Completing-the-Rating-Decision-Narrative\">M21-1, Part V, Subpart iv, 1.A</a>, CBRNE rating decisions must follow the below guidelines.</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">Since CBRNE is considered TERA participation, the rating decision must follow the TERA rating guidance outlined in the <a href=\"https://vbaw.vba.va.gov/bl/21/pact.htm\" target=\"_blank\"><i>PACT Implementation SOP</i></a>.</span></span></div></li><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When denying SC because an <i>explicit</i> allegation of CBRNE test participation could not be established, the rating decision must include the following free text to the rating narrative:  </span></span></div></li></ul><div style=\"margin-left: 80px;\"><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><i>You reported participating in Chemical Biological Radiological Nuclear and Explosives (CBRNE) testing. The evidence of record does not show you participated in CBRNE testing</i>.</span></span></div><ul><li><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\">When completing the SUBJECT field on the ISSUE MANAGEMENT tab in Veterans Benefits Management System – Rating (VBMS-R), end the description of the disability with <em>[CBRNE]</em> regardless of whether the issue is being awarded or denied.  This will clearly identify the CBRNE claimed issues, or those issues which the decision maker has decided are related to CBRNE testing, on the <em>Codesheet</em>.</span></span></div></li></ul></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>Example</em></strong>:  <em>Scar, right upper extremity [CBRNE]</em>.</span></span></div><div></div><div><span style=\"font-size:14px;\"><span style=\"font-family:Arial,Helvetica,sans-serif;\"><strong><em>Reference</em></strong>:  For more information on entering decisions in VBMS-R, see the <em>VBMS Rating User Guide</em>.</span></span></div></td></tr></tbody></table><div class=\"ng-scope\" style=\"margin-left: 85pt\"><hr/></div><div class=\"ng-scope\" style=\"margin-left: 85pt\"><span style=\"font-size: 14px\"><span style=\"font-family: arial , helvetica , sans-serif\"> </span></span></div><div class=\"ng-scope\" style=\"text-align: right\"><span style=\"font-size: 11px\"><span style=\"font-family: Arial,Helvetica,sans-serif\"><a articleid=\"554400000177457\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 5, Section A - Developing Claims Based on Participation in Chemical Biological Radiological Nuclear and Explosives (CBRNE) Testing\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177457/M21-1-Part-VIII-Subpart-iii-Chapter-5-Section-A-Developing-Claims-Based-on-Participation-in-Chemical-Biological-Radiological-Nuclear-and-Explosives-CBRNE-Testing\">&lt;-- Previous Section</a>  <a articleid=\"554400000177459\" articlename=\"M21-1, Part VIII, Subpart iii, Chapter 6, Section A - Developing Claims Based on Participation in Project Shipboard Hazard and Defense (SHAD)\" articleviewcontext=\"article_view_related_article\" class=\"eGainArticleLink\" eg-link-click=\"\" href=\"/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177459/M21-1-Part-VIII-Subpart-iii-Chapter-6-Section-A-Developing-Claims-Based-on-Participation-in-Project-Shipboard-Hazard-and-Defense-SHAD\">Next Section --&gt;</a></span></span></div><p class=\"ng-scope\">                <span style=\"font-family: arial , helvetica , sans-serif\"><a href=\"#top\" target=\"_self\"><span style=\"font-size: 11px\">To Top</span></a></span></p><p class=\"ng-scope\"></p></div>\n</div>",
  "external_links": [
    "http://www.ecfr.gov/cgi-bin/text-idx?SID=a88986ca8f9a29e8af73cdffa7bc08f9&node=se38.1.3_1303&rgn=div8",
    "https://vbaw.vba.va.gov/bl/21/pact.htm"
  ],
  "scraped_at": "2025-06-16T22:58:55.658761",
  "next_section": "https://www.knowva.ebenefits.va.gov/system/templates/selfservice/va_ssnew/help/customer/locale/en-US/portal/554400000001018/content/554400000177459/M21-1-Part-VIII-Subpart-iii-Chapter-6-Section-A-Developing-Claims-Based-on-Participation-in-Project-Shipboard-Hazard-and-Defense-SHAD"
}